PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
  • Start-up from Imperial College London and the Francis Crick Institute brings together 15 years of world-leading research on N-myristoyltransferase (NMT) and breakthrough discoveries related to its inhibition in cancer
  • Initial financing of £4.5M from venture capital syndicate of experienced life sciences investors, Sofinnova Partners and Brandon Capital Partners
  • Led by a team of world-class scientists and drug developers with a track record of big pharma/biotech and academic successes

Stevenage, UK, November 16, 2020 - Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brandon Capital Partners.

Myricx is a start-up from the UK’s leading biomedical research organisations, Imperial College London and the Francis Crick Institute. The Company is based on over 15 years of world-leading NMT biology and chemistry research from the laboratories of its co-founders, Professor Ed Tate, Chief Scientific Officer, Dr Andrew Bell, Chemistry Consultant, and Dr Roberto Solari, Chief Executive Officer. Myricx has the rights to key NMT discoveries, and composition-of-matter and use patents of its scientific co-founders through exclusive license agreements with Imperial College London.

The Company is pursuing NMT inhibition in a variety of indications with an initial focus in oncology exploiting novel breakthrough discoveries that identified that inhibition …

Read More...
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer

Articles